MARÍA
GÓMEZ CAÑAS
Profesora ayudante doctora
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublications en collaboration avec des chercheurs de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (21)
2023
-
Endocannabinoid-Binding Receptors as Drug Targets
Methods in molecular biology (Clifton, N.J.), Vol. 2576, pp. 67-94
2022
-
Editorial: Cannabinoids as potential treatment for neurological diseases
Frontiers in Neuroscience
2021
-
Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease
European Journal of Pharmacology, Vol. 895
-
Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease
Molecules, Vol. 26, Núm. 11
-
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Molecular and Cellular Neuroscience, Vol. 110
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
2020
-
Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors
British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 4034-4054
2019
2018
-
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor
Journal of Neuroinflammation, Vol. 15, Núm. 1
-
Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists
Bioorganic and Medicinal Chemistry, Vol. 26, Núm. 1, pp. 295-307
-
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways
British Journal of Pharmacology, Vol. 175, Núm. 19, pp. 3813-3831
2017
-
Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)
Pharmacological Research
-
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412
2016
-
Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
Pharmacological Research, Vol. 110, pp. 205-215
-
Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators
Cannabis and Cannabinoid Research, Vol. 1, Núm. 1, pp. 196-201
-
Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology
Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1840-1853
-
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
Scientific Reports, Vol. 6
-
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties
European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80
2015
-
Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists
European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667
2014
-
Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling
Journal of Biological Chemistry, Vol. 289, Núm. 32, pp. 21960-21972